Leu-Leu-Val-Tyr | 99542-45-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Leu-Leu-Val-Tyr
• 英文别名: LLVY；H-Leu-Leu-Val-Tyr-OH；(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
• CAS: 99542-45-7
• 化学式: C₂₆H₄₂N₄O₆
• 分子量: 506.643
• InChiKey: UBBRXQXPXQRQDT-CMOCDZPBSA-N

物化性质

• 沸点：
  808.1±65.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  36
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  171
• 氢给体数：
  6
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Leu-Leu-Val-Tyr 在 氰基磷酸二乙酯 、 三乙胺 、 溶剂黄146 作用下， 以 水 、 乙腈 、 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 反应 3.0h， 以21%的产率得到cyclo(Leu-Leu-Val-Tyr)
  参考文献：
  名称：

  Lin, Yee-Fung; Lee, Shih-Ming; Chen, Chi-Tai, Journal of the Chinese Chemical Society, 2009, vol. 56, # 1, p. 127 - 134

  摘要：

  DOI：

文献信息

• Compounds for enzyme inhibition
  申请人：Smyth S. Mark

  公开号：US20050245435A1

  公开（公告）日：2005-11-03

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  基于肽的化合物，包括含杂原子的三元环，能够高效且选择性地抑制N-末端亲核试剂（Ntn）水解酶的特定活性。描述的化合物可以差异性地抑制具有多种活性的Ntn的活性。例如，20S蛋白酶体的胰凝乳样活性可以被这些新颖化合物选择性地抑制。这些基于肽的化合物包括至少三个肽单元，一个环氧或环丙胺，以及N-末端的功能化。除了其他治疗用途外，这些基于肽的化合物预计将显示抗炎性和细胞增殖抑制作用。
• COMPOUNDS FOR ENZYME INHIBITION
  申请人：Smyth Mark S.

  公开号：US20120101048A1

  公开（公告）日：2012-04-26

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  基于肽的化合物包括含杂原子的三元环，可以高效且选择性地抑制N-末端亲核试剂（Ntn）水解酶的特定活性。所述化合物可以差异性地抑制具有多种活性的Ntn的活性。例如，20S蛋白酶体的胰凝乳样活性可以通过该发明的化合物被选择性地抑制。基于肽的化合物包括至少三个肽单元，环氧或氮杂环以及N-末端的功能化。在其他治疗用途中，基于肽的化合物预计将显示抗炎性和细胞增殖抑制作用。
• Compounds For Enzyme Inhibition
  申请人：Smyth Mark S.

  公开号：US20080200398A1

  公开（公告）日：2008-08-21

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  肽基化合物包括含杂原子的三元环，能够高效且选择性地抑制N-末端亲核试剂（Ntn）水解酶的特定活性。所述化合物可以不同程度地抑制具有多种活性的Ntn的活性。例如，创新化合物可以选择性地抑制20S蛋白酶体的胰蛋白酶样活性。肽基化合物包括至少三个肽单元，一个环氧化物或环氮化物，以及N-末端的功能化。除其他治疗用途外，预计肽基化合物将显示抗炎性和细胞增殖抑制作用。
• Compounds for proteasome enzyme inhibition
  申请人：Proteolix, Inc.

  公开号：EP2100899A2

  公开（公告）日：2009-09-16

  The present invention relates to a method for determining the activity of a proteasome inhibitor, comprising (a) obtaining a biological sample that has been treated with a proteasome inhibitor; (b) separating inhibitor-bound proteasome subunits from unbound proteasome subunits; (c) determining the amount of inhibitor-bound proteasome subunits, unbound proteasome subunits, or both, wherein a change in the amount of inhibitor bound proteasome subunits is indicative of proteasome inhibitor activity.

  本发明涉及一种确定蛋白酶体抑制剂活性的方法，该方法包括：(a) 获得用蛋白酶体抑制剂处理过的生物样本；(b) 将抑制剂结合的蛋白酶体亚基与未结合的蛋白酶体亚基分离；(c) 确定抑制剂结合的蛋白酶体亚基、未结合的蛋白酶体亚基或两者的量，其中抑制剂结合的蛋白酶体亚基量的变化表明蛋白酶体抑制剂的活性。
• Enzyme inhibition
  申请人：Yale University

  公开号：US20040266664A1

  公开（公告）日：2004-12-30

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.

  包括含杂原子的三元环的肽基化合物能有效地、选择性地抑制 N 端亲核（Ntn）水解酶的特定活性。具有多种活性的 Ntn 的活性可受到所述化合物不同程度的抑制。例如，本发明化合物可选择性地抑制 20S 蛋白酶体的糜蛋白酶样活性和 PGPH 活性。肽基化合物包括一个邻近环官能团的退电子基团，肽包括至少三个肽单元。除其他治疗作用外，肽基化合物还具有抗炎和抑制细胞增殖的作用，涉及这些化合物的治疗应用。